Human Pathology
Volume 36, Issue 5 , Pages 465-473 , May 2005

Mesothelioma with clear cell features: an ultrastructural and immunohistochemical study of 20 cases

Received 3 November 2004 ,Accepted 7 February 2005.

References 

  1. Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology. 1997;30:403–418
  2. Hammar SP. Pleural disease. In:  Dail DH,  Hammar SP editor. Pulmonary pathology. 2nd ed.. New York: Springer-Verlag; 1994;p. 1463–1579
  3. Ordóñez NG. Epithelial mesothelioma with deciduoid features: report of four cases. Am J Surg Pathol. 2000;24:816–823
  4. Ordóñez NG, Myhre M, Mackay B. Clear cell mesothelioma. Ultrastruct Pathol. 1996;20:331–336
  5. Cavazza A, Pasquinelli G, Agostini L, et al. Foamy cell mesothelioma. [Letter] Histopathology. 2002;41:369–371
  6. Dessy E, Falleni M, Braidotti P, et al. Unusual clear cell variant of epithelioid mesothelioma. Arch Pathol Lab Med. 2001;125:1588–1590
  7. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031–1051
  8. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. hum path. 2004;35:697–710
  9. Ordóñez NG, Mackay B. Glycogen-rich mesothelioma. Ultrastruct Pathol. 1999;23:401–406
  10. Chang HT, Yantiss RK, Nielsen GP, et al. Lipid-rich diffuse malignant mesothelioma: a case report. hum path. 2000;31:876–879
  11. Kitazawa M, Kaneko H, Toshima M, et al. Malignant peritoneal mesothelioma with massive foamy cells: codfish roe–like mesothelioma. Acta Pathol Jpn. 1984;34:687–692
  12. Dickersin GR, Vickery AL, Smith SB. Papillary carcinoma of the thyroid, oxyphil cell type, “clear cell” variant: a light and electron microscopic study. Am J Surg Pathol. 1980;4:501–509
  13. Carcangiu ML, Sibley RK, Rosai J. Clear cell change in primary thyroid tumors: a study of 38 cases. Am J Surg Pathol. 1985;9:705–722
  14. Ordóñez NG, Mackay B, El-Naggar A, et al. Clear cell carcinoid tumor of the stomach. Histopathology. 1993;22:190–193
  15. Kwon TJ, Ro JY, Mackay B. Clear-cell carcinoma: an ultrastructural study of 57 tumors from various sites. Ultrastruct Pathol. 1996;20:519–527
  16. Landon G, Ordóñez NG. Clear cell variant of medullary carcinoma of the thyroid. hum path. 1985;16:844–847
  17. Thoenes W, Baum HP, Störkel S, et al. Cytoplasmic microvesicles in chromophobe cell renal carcinoma demonstrated by freeze fracture. Virchows Arch. 1987;54:127–130
  18. Thoenes W, Störkel S, Rumpelt H-J, et al. Chromophobe cell renal carcinoma and its variants: a report on 32 cases. J Pathol. 1988;155:277–287
  19. Shimazaki H, Aida S, Iizuka Y, et al. Vacuolated cell mesothelioma of the pericardium resembling liposarcoma: a case report. hum path. 2000;31:767–770
  20. Hammar SP, Bockus DE, Remington FL, et al. Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas. Ultrastruct Pathol. 1996;20:293–325
  21. Dumke K, Schnoy N, Specht G, et al. Comparative light and electron microscopic studies of cystic and papillary tumors of the peritoneum. Virchows Arch Pathol Anat. 1983;399:25–39
  22. Ordóñez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol. 1998;11:929–933
  23. Ordóñez NG. Value of keratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol. 1998;22:1215–1221
  24. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003;16:192–197
  25. Ordóñez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, and CD44S immunostaining in distinguishing epithelioid pleural mesothelioma from pulmonary and non-pulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598–606
  26. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116:823–830
  27. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443:122–132
  28. Wu M, Wang B, Gil J, et al. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol. 2003;119:696–702
  29. Pan C-C, Chen PC-H, Chou T-Y, et al. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. hum path. 2003;34:1155–1162
  30. Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology. 1996;29:209–215
  31. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology. 1997;31:140–143
  32. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996;20:1037–1046
  33. Dardick I, Jabi M, McCaughey WTE, et al. Diffuse epithelial mesothelioma: a review of the ultrastructural spectrum. Ultrastruct Pathol. 1987;11:503–533
  34. Ordóñez NG, Mackay B. The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma. Adv Anat Pathol. 1996;3:273–293
  35. Oury TD, Hammar SP, Roggli VL. Ultrastructural features of diffuse malignant mesotheliomas. hum path. 1998;29:1382–1392

PII: S0046-8177(05)00083-3

doi: 10.1016/j.humpath.2005.02.014

Human Pathology
Volume 36, Issue 5 , Pages 465-473 , May 2005

Article Tools

* Image Usage & Resolution